We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.73 | 1.87% | 39.80 | 40.12 | 39.58 | 39.63 | 3,064,146 | 01:00:00 |
From Jul 2023 to Jul 2024
By Ian Walker
GSK PLC raised its full-year guidance after third-quarter net profit rose, although it missed analysts' forecasts.
The British pharmaceutical giant attributed its strong performance mainly to the launch of its first respiratory syncytial virus vaccine, Arexvy, in the U.S.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
November 01, 2023 03:35 ET (07:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
